logo
Two moon missions touched down on the lunar surface. How they unfolded was a stark contrast

Two moon missions touched down on the lunar surface. How they unfolded was a stark contrast

CNN08-03-2025

Each time a robotic explorer launches from Earth, it faces innumerable challenges — any of which could cut the mission short.
California-based asteroid mining company AstroForge shared on Thursday that its Odin spacecraft, which ventured to space a week and a half ago with Intuitive Machines' Athena lunar lander, met an untimely end.
The probe was heading for an asteroid to scout for the valuable resource platinum. But Odin's team said the vehicle is likely tumbling through space, with little hope of restoring communications.
Space is hard, and every bold mission adds lessons learned. This week, a tale of two lunar landers demonstrates why scientists and engineers always expect the unexpected in the saga of space exploration.
Defying gravity
On March 2, Firefly Aerospace's Blue Ghost lunar lander touched down on the moon, making it the second private sector company to execute the feat.
Photos showcasing the spacecraft's dramatic shadow on the lunar surface and its feet within moon dust confirmed the mission's success.
The Cedar Park, Texas-based company has since shared a video of the lander's nail-biting descent just north of the moon's equator.
Blue Ghost will spend the next week collecting samples, drilling into the subsurface and capturing high-definition imagery.
Lunar update
The Athena lander also made it to the moon, after descending near the lunar south pole on Thursday in hopes of conducting a water-finding mission.
Initially, Intuitive Machines was scrambling to determine the spacecraft's orientation. But images from Athena's suite of cameras helped confirm that the mission ended prematurely, with the lander lying on its side inside a crater.
The lander is 820 feet (250 meters) from the target landing site of Mons Mouton, a flat-topped mountain, the Houston-based company said.
Before powering down, Athena briefly operated and transmitted data, making it the 'southernmost lunar landing and surface operations ever achieved,' according to the company.
Back to the future
Meet the woolly mouse, genetically modified to have several woolly mammoth-like traits.
Engineered by Colossal Biosciences, the mice have curly whiskers and hair that grows three times longer than that of typical lab mice.
Colossal is attempting to resurrect mammoths and other extinct creatures, and the mice will enable its team to test links between specific genetic sequences and physical traits that enabled the giants to endure bitterly cold environments, according to the private Dallas company.
But the new study doesn't address whether the modified mice are actually tolerant of the cold, said Robin Lovell-Badge, head of the Stem Cell Biology and Developmental Genetics Laboratory at The Francis Crick Institute in London.
'As it is, we have some cute looking hairy mice, with no understanding of their physiology, behaviour, etc,' Lovell-Badge said via email.
Force of nature
The adventure of the world's biggest iceberg, known as A23a, may have come to an end after it spent five years wandering the Southern Ocean near Antarctica and, for a time, spinning around an undersea mountain.
The 'megaberg,' weighing 1.1 trillion tons (nearly 1 trillion metric tonnes) and slightly smaller than Rhode Island, ran aground on the island of South Georgia in the southern Atlantic Ocean.
'Nutrients stirred up by the grounding and from its melt may boost food availability for the whole regional ecosystem, including for charismatic penguins and seals,' said Andrew Meijers, an oceanographer at the British Antarctic Survey.
Now, scientists are trying to predict what will happen to A23a next, and what impact the iceberg will have if it splits into pieces.
A long time ago
Archaeologists have uncovered a cache of tools that ancient human ancestors crafted from elephant and hippopotamus bones 1.5 million years ago in Olduvai Gorge, known as the 'Cradle of Humankind,' in Tanzania.
The unexpected discovery makes these the oldest known bone tools by about 1 million years. The 27 bone fragments appear to have been systematically sharpened and shaped using stone.
Researchers believe our early human ancestors took the same sophisticated techniques they used to make stone tools and applied them to carefully selected limb bones from large animals.
The finding suggests that hominins were capable of critical thinking and innovative craftsmanship, but scientists are still trying to figure out who exactly made the tools.
Explorations
Let your curiosity ascend to new heights with these stories:
— For the second time this year, SpaceX's megarocket Starship exploded midflight during a test mission, disrupting air traffic and raining down flaming debris that was captured on video by onlookers in the Caribbean.
— The narwhal is often called the 'unicorn of the sea' because of its signature spiral tusk. Now, scientists have recorded the first video evidence revealing some surprising ways the Arctic whales use their tusks, including for playful behavior.
— The twin Voyager probes are each turning off a science instrument to conserve power and prevent both historic missions from ending within a few months.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030

Yahoo

time15 minutes ago

  • Yahoo

$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030

The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Could Liquid Biopsy Guide Treatment in Cervical Cancer?
Could Liquid Biopsy Guide Treatment in Cervical Cancer?

Medscape

time37 minutes ago

  • Medscape

Could Liquid Biopsy Guide Treatment in Cervical Cancer?

Circulating tumor DNA (ctDNA) levels in patients with cervical cancer before and during treatment were prognostic of disease progression and survival in a post hoc analysis of the phase 3 CALLA trial. The findings 'support the future utility of…ctDNA analysis to help guide treatment decisions for locally advanced cervical cancer,' said lead study author Jyoti Mayadev, MD, a radiation oncologist at Moores NCI-Designated Comprehensive Cancer Center and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine in La Jolla, California. Mayadev reported the results at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. They were published simultaneously in the Annals of Oncology . The previously published CALLA trial showed that patients receiving adjuvant chemoradiotherapy (CRT) for locally advanced cervical cancer did not have improved progression-free survival (PFS) with the addition of concurrent durvalumab compared with placebo. The trial included 770 patients with previously untreated stage IB2-IIB node-positive or IIIA-IVA any node-status locally advanced cervical cancer who were randomly assigned to receive durvalumab (1500 mg intravenously once every 4 weeks) plus CRT (n = 385) or CRT alone (n = 385). CRT, consisting of external beam radiotherapy with intravenous cisplatin or carboplatin, was delivered once weekly for 5 weeks, followed by image-guided brachytherapy. Exploratory Analysis Methods and Results A preplanned exploratory analysis sampled ctDNA levels in a subset of 186 patients to determine if ctDNA could serve as a biomarker for treatment response. The study used an ultrasensitive tumor-informed ctDNA assay, personalized for each patient, to test plasma at baseline, cycle 3 day 1 (immediately post-CRT), and cycle 6 day 1 (3 months post-CRT), explained Mayadev during her presentation at the meeting. ctDNA was detected in 99% of baseline samples, with no difference across the treatment arms, she reported. Immediately after treatment, detectable levels decreased to 35.5% in the durvalumab/CRT arm and 39.8% in the CRT-only arm. By 3 months after treatment, levels declined further to 23.4% and 36.4%, respectively, demonstrating a 13% lower rate of detectable ctDNA in the durvalumab/CRT arm at this timepoint. The study showed that ctDNA levels were prognostic of both PFS and overall survival (OS), regardless of treatment arm. Among patients in whom ctDNA was detectable immediately posttreatment, 68% subsequently progressed, and among those without detectable ctDNA, 83% had not progressed by the time of data cutoff, for a positive predictive value of 61%, a negative predictive value of 83%, and a sensitivity and specificity of 68% and 78%, respectively. ctDNA Detected 5.5 Months Before Radiographic Progression The median lead time from ctDNA detection on the ultrasensitive assay until radiographic or clinical evidence of progression was 5.5 months, ranging from 1.5 to 16.5 months. Looking specifically at PFS and OS, patients with ctDNA levels were prognostic of PFS and OS for patients in both treatment arms at all timepoints measured. In the durvalumab/CRT arm, low vs high ctDNA at baseline conferred a hazard ratio of 0.60 for PFS and of 0.63 for OS. In the CRT-only arm, low vs high ctDNA conferred hazard ratios of 0.62 and 0.85 for PFS and OS, respectively. Similarly, detectable ctDNA levels immediately posttreatment compared with undetectable levels identified patients at a higher risk for progression and death, regardless of treatment arm. With detectable ctDNA as the reference, PFS and OS hazard ratios were 0.23 and 0.20 in the durvalumab/CRT arm and 0.15 and 0.18 in the CRT-only arm, respectively. Having no ctDNA detected 3 months after treatment cessation reduced the risks for progression and death by at least 95% for patients in both treatment arms, Mayadev said during her presentation. Multivariate analysis showed that detection of ctDNA immediately posttreatment conferred a hazard ratio of 5.27 ( P < .001) for PFS, independent of disease stage at baseline or treatment allocation, she said. 'Our study found that persistent ctDNA levels posttreatment strongly correlated with an increased risk of relapse and were likely reflective of residual disease that, in some instances, went undetected by other means,' wrote Mayadev and co-authors in their paper. 'On average, ctDNA was detected 5.5 months before radiographic progression. In clinical practice, this could allow for proactive treatment management to potentially improve patient outcomes — for example, earlier consideration of adjuvant therapies, such as immunotherapy or systemic therapy, or a switch to a novel therapeutic regimen. In cases of recurrence, tracking ctDNA levels in real-time could also help assess response to salvage therapy, providing a dynamic tool for optimizing therapeutic decisions.' 'This really is a good analysis showing how ctDNA is definitely a better prognostic marker than standard poor prognostic clinical factors such as nodal status and even updated FIGO staging for cervical cancer,' said Mark Einstein, MD, the discussant for the paper, who is professor and chair of the Department of Obstetrics and Gynecology and Women's Health at Montefiore Medical Center/Albert Einstein College of Medicine, New York City. However, he said the positive predictive value and sensitivity 'are good, but they're not great. The negative predictive value, though, is excellent, and this would reveal that the test might have some value as a negative predictive marker of recurrence rather than a positive predictive marker of recurrence.' But, the bigger question, he said, is 'what are we going to do with that information? If we actually do know that someone has a positive ctDNA, are we going to get into the situation that we are in with ovary cancer, with CA125 without measurable disease, where it just creates a lot of anxiety without necessarily restarting treatment? This could identify central disease before it actually becomes distant, which could lead to potentially curative surgical options, and it might put someone on increased surveillance in imaging, but I think we need to really look at this prospectively.' Also commenting on the study, Sarah Kim, MD, a gynecologic surgeon specializing in the treatment of ovarian, endometrial, cervical, vulvar, and vaginal cancer at the Memorial Sloan Kettering Cancer Center in New York City, pointed out what she found useful and what additional questions need to be answered. 'Further studies need to be done to validate these results and determine the clinical utility in the setting of adjuvant therapy or recurrence,' she said in an interview with Medscape Medical News . 'I think these are important findings and potentially clinically impactful for patients with locally advanced cervical cancer,' said Kim. 'They support the use of ctDNA to detect minimal residual disease and/or the use of ctDNA as a prognostic marker, which is lacking in cervical cancer. We have seen similar results in patients with endometrial cancer, where the ctDNA increases prior to any detection of disease on imaging.' The trial was sponsored by AstraZeneca. Mayadev disclosed leadership roles with the American Brachytherapy Society and NRG Oncology; honoraria from AstraZeneca; consulting or advisory roles with Agenus, AstraZeneca/MedImmune, Merck, Primmune Therapeutics, and Varian Medical Systems; research funding from Varian Medical Systems; and travel, accommodations, and other expenses from Merck. Einstein disclosed a consulting or advisory role with Antiva Biosciences, Asieris Pharmaceuticals, and Merck, and research funding from Johnson & Johnson, Merck, and PapiVax Biotech, Inc. Kim had no disclosures.

Private Japanese lunar lander closing in on unexplored top of the moon
Private Japanese lunar lander closing in on unexplored top of the moon

CBS News

time2 hours ago

  • CBS News

Private Japanese lunar lander closing in on unexplored top of the moon

A private lunar lander from Japan is closing in on the moon, aiming for a touchdown in the unexplored far north with a mini rover. The moon landing attempt by Tokyo-based company ispace on Friday Japan time is the latest entry in the rapidly expanding commercial lunar rush. This image provided by ispace, inc. shows the Resilience lander circling the moon on June 4, 2025. ispace, inc. via AP The encore comes two years after the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience holds a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house that will be lowered onto the moon's dusty surface. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience is targeting the top of the moon, a less forbidding place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Once settled with power and communication flowing, the 7.5-foot Resilience will lower the piggybacking rover onto the lunar surface. Made of carbon fiber-reinforced plastic with four wheels, ispace's European-built rover - named Tenacious - sports a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 11 pounds, will stick close to the lander, going in circles at a speed of less than one inch per second. Besides science and tech experiments, there's an artistic touch. The rover holds a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg for placement on the lunar surface. Takeshi Hakamada, CEO and founder of ispace, considers the latest moonshot "merely a steppingstone," with its next, much bigger lander launching by 2027 with NASA involvement, and even more to follow. "We're not trying to corner the market. We're trying to build the market," Jeremy Fix, chief engineer for ispace's U.S. subsidiary, said at a conference last month. "It's a huge market, a huge potential." Fix noted that ispace, like other businesses, does not have "infinite funds" and cannot afford repeated failures. While not divulging the cost of the current mission, company officials said it's less than the first one, which exceeded $100 million. Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store